The Greek pharmaceutical industry has reached its limits due to a number of “unreasonable” burdens imposed by the government during the crisis, Greek pharma chief Olympios Papadimitriou told EURACTIV.com in an interview. The sustainability of pharma companies is at stake, threatening 86,000 jobs, he said.
Austria's EU Presidency will focus on "strong" investment in digital health as well as on regulatory issues when it comes to access to medicines, Dr Clemens Martin Auer told EURACTIV.com in an interview. Dr Clemens Martin Auer is the president of the European …
“Salami-slicing” the cost of medicines, which represent almost one-fifth of health system budgets and are subject to rigorous value assessments, won’t make healthcare systems more sustainable in the future, Nathalie Moll told EURACTIV.com in an interview.
Patients are “punished” due to a lack of innovation-driven structural reforms in a crisis-hit public health system, the head of the Greek pharma industry said in an interview with Euractiv Greece.
There is a great need to raise awareness and enhance education on diabetes and a healthier lifestyle “at every level”, Stella de Sabata, head of the International Diabetes Federation, told EURACTIV.com.
The Maltese EU presidency will seek more transparency in the way pharmaceutical companies negotiate with member states on medicines’ pricing, Health Minister Chris Fearne said in an interview with EURACTIV.
Alzheimer’s disease and other forms of dementia remain underdiagnosed in most European countries, Jean Georges told EURACTIV.
Bulgaria and Romania will soon sign an intergovernmental agreement to jointly negotiate the pricing and availability of medicines with pharmaceutical companies, Bulgarian Health Minister Petar Moskov said in an interview with EURACTIV.com.
A new breed of drugs, called “value added medicines”, could help patients improve their everyday life while in treatment, without increasing healthcare budgets, Christoph Stoller said in an interview with EURACTIV.com
